MTPConnect Chair Hon Jaala Pulford introduced compelling presentations from Avance Clinical, Scientia Clinical Research, 360biolabs, a BioAgilytix company, IDT Australia Limited and Acclime detailing why Australia is such a go-to destination for companies wanting to conduct clinical trials.
And great to hear from Sungmin Song from leading Korean pharma company JD BIOSCIENCE about their experiences working in Australia – high quality health system, efficient regulatory process, great infrastructure, ethnically diverse patient pools and financial incentives are all part of the Australian offer and make the world of difference.
The event is another example of MTPConnect’s commitment to commercially-focused collaboration to create new business, investment, market and partnering opportunities for Australia’s life science companies.
And as Australia’s fourth largest two-way trading partner, leveraging these connections is more important than ever before, with the emergence of a significant new trading, supply chain and security block between Korea, China and Japan.
Grateful for support from the governments of Victoria, NSW and South Australia to make this happen – and special shout-out to Austrade’s Trade and Investment Director in Seoul, Juliet Woo.